We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
-2.4%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.32B
AUM Growth
-$216M
(-3.9%)
Cap. Flow
-$62.5M
Cap. Flow
% of AUM
-1.18%
Top 10 Holdings %
Top 10 Hldgs %
23.94%
Holding
294
New
29
Increased
89
Reduced
98
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$46.6M |
| 2 |
Gilead Sciences
GILD
|
+$37M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$31.1M |
| 4 |
CVS Health
CVS
|
+$27.8M |
| 5 |
Danaher
DHR
|
+$26.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$36.5M |
| 2 |
PNC Financial Services
PNC
|
+$34.3M |
| 3 |
CELG
Celgene Corp
CELG
|
+$32.4M |
| 4 |
AGN
Allergan plc
AGN
|
+$28M |
| 5 |
Centene
CNC
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.2% |
| 2 | Healthcare | 23.21% |
| 3 | Financials | 21.91% |
| 4 | Communication Services | 9.94% |
| 5 | Industrials | 5.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.89T
| $200M | 3.76% |
7,333,956
+370,636
| +5% | +$9.23M |
|
2
Alphabet (Google) Class C
GOOG
$3.9T
| $186M | 3.49% |
4,985,580
-470,220
| -9% | -$16.8M |
|
3
Johnson & Johnson
JNJ
$634B
| $182M | 3.42% |
1,681,519
-17,523
| -1% | -$1.81M |
|
4
Chubb
CB
$140B
| $135M | 2.55% |
1,136,029
+64,340
| +6% | +$7.39M |
|
5
Microsoft
MSFT
$2.84T
| $108M | 2.04% |
1,961,866
-128,329
| -6% | -$6.73M |
|
6
Meta Platforms (Facebook)
META
$1.51T
| $108M | 2.04% |
948,656
+13,266
| +1% | +$1.4M |
|
|
7
Alphabet (Google) Class A
GOOGL
$3.91T
| $95.6M | 1.8% |
2,508,020
-33,400
| -1% | -$1.23M |
|
8
Berkshire Hathaway Class B
BRK.B
$1.07T
| $90.5M | 1.7% |
637,889
+197,109
| +45% | +$26.1M |
|
9
Pfizer
PFE
$140B
| $83.9M | 1.58% |
2,983,912
+103,073
| +4% | +$2.94M |
|
10
Arch Capital
ACGL
$36.1B
| $83.4M | 1.57% |
3,520,368
-15,342
| -0.4% | -$349K |
|
11
Markel Group
MKL
$25B
| $82.6M | 1.55% |
92,696
-3,530
| -4% | -$3.03M |
|
12
Visa
V
$677B
| $79.7M | 1.5% |
1,041,866
-32,549
| -3% | -$2.36M |
|
13
Intel
INTC
$464B
| $73.1M | 1.37% |
2,258,741
-250,609
| -10% | -$7.69M |
|
14
JPMorgan Chase
JPM
$939B
| $70.3M | 1.32% |
1,187,022
+168,463
| +17% | +$9.84M |
|
15
Citigroup
C
$222B
| $68.8M | 1.29% |
1,648,288
+289,502
| +21% | +$12.1M |
|
|
VR
16
DELISTED
Validus Hold Ltd
VR
| $68.6M | 1.29% |
1,453,363
+55,810
| +4% | +$2.51M |
|
|
BCR
17
DELISTED
CR Bard Inc.
BCR
| $68.5M | 1.29% |
337,992
+164,596
| +95% | +$31.1M |
|
18
Amdocs
DOX
$5.53B
| $64.9M | 1.22% |
1,073,479
+177,023
| +20% | +$9.91M |
|
19
Elevance Health
ELV
$81.9B
| $63.8M | 1.2% |
459,317
-1,995
| -0.4% | -$267K |
|
20
Fidelity National Information Services
FIS
$21.5B
| $62.4M | 1.17% |
985,131
-3,088
| -0.3% | -$185K |
|
21
Medtronic
MDT
$107B
| $60.3M | 1.13% |
803,357
-341,719
| -30% | -$25.7M |
|
22
PepsiCo
PEP
$186B
| $57.9M | 1.09% |
564,540
-645
| -0.1% | -$63.7K |
|
|
QVCGA
23
DELISTED
QVC Group Inc Series A
QVCGA
| $57.2M | 1.08% |
46,640
-63
| -0.1% | -$76.8K |
|
24
Eli Lilly
LLY
$1.07T
| $57.2M | 1.08% |
793,778
-41,222
| -5% | -$3.12M |
|
25
Accenture
ACN
$89.9B
| $57.1M | 1.08% |
495,189
-259,089
| -34% | -$26.6M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q1 2016 Portfolio in Review
As of Q1 2016, Polar Capital held 294 positions worth $5.32B, down 3.9% from $5.53B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Polar Capital's Q1 2016 filing shows 29 new, 89 increased, 98 reduced and 32 closed positions. Its largest new stake was Union Pacific: 603,004 shares worth $48M. The largest sale was Bristol-Myers Squibb, an estimated $36.5M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
- Polar Capital's largest Q1 2016 buy was Union Pacific: 603,004 shares worth $48M.
- Polar Capital added most to Gilead Sciences in Q1 2016, an estimated $37M increase.
- Polar Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $36.5M.
- Polar Capital fully exited Centene in Q1 2016, selling an estimated $27.3M.
- Polar Capital's ten largest holdings make up 24% of its $5.32B portfolio in Q1 2016.
- Polar Capital opened 29 new positions and closed 32 in Q1 2016.
- Polar Capital's portfolio value fell 3.9% quarter-over-quarter to $5.32B.
Based on Polar Capital's 13F filing for Q1 2016, filed 16 May 2016.